ClinicalTrials.gg

Program

HXN-1013

A development code.

Its studies are mostly in Asthma, led by Helixon Biotechnology (Suzhou).

Furthest: phase 1, since Oct 21, 20261 company-led study, 1 open or runningNext primary completion: Feb 15, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Helixon Biotechnology (Suzhou)11 open or runningphase 1since Oct 21, 2026Oct 21, 2026Feb 15, 2028phase 1 · NCT07900568

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2026First study: phase 1 study in AsthmaFirst studyNCT07900568 · 40 planned · Australia

Ahead

  1. Feb 15, 2028Primary completion: phase 1 study in AsthmaNCT07900568

TargetBeta

IL33 →TSLP →read by rule
“HXN-1013 is a recombinant humanized bispecific antibody simultaneously targeting thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33).”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07900568Asthma · Australia1Not yet recruitingFeb 15, 202840

How it is read

Names in the registry

  • “HXN-1013”, 1 entry

Codes read as this program: HXN1013.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.